Skip to main content
Premium Trial:

Request an Annual Quote

Seeking to Free Itself from Filing Fees, Lion Bioscience Asks SEC to Terminate Registration

NEW YORK, May 19 (GenomeWeb News) - Hoping to save more money, Lion Bioscience today filed a request with the SEC to terminate the registration of the company's ordinary shares with the agency, Lion said in a statement.

 

Lion said it expects this termination to become effective 90 days after its filing with the SEC. The filing frees the company from the obligation to file annual reports and other forms with the agency, Lion added.

 

The company will continue to provide shareholders financial information as required by the Frankfurt exchange and German law, Lion said.

 

As GenomeWeb News reported last year, Lion had delisted its American Depositary Shares from the Nasdaq National Market and terminated its American Depositary Receipt facility after the end of trading on Dec. 22. JP Morgan Chase Bank had sold on the German stock market "the underlying ordinary shares as to which [Lion's] ADSs had not been surrendered" to the bank by February 22, the statement said. 

 

The bank will hold the proceeds of the sales for the pro rata benefit of registered holders of ADSs that have not been surrendered, and these holders may contact the JP Morgan for their share, the company added.

 

The total number of shares outstanding are unaffected by deregistration with the SEC, the company said.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.